You are here » Home » Companies » Company Overview » Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd.

BSE: 506197 Sector: Health care
NSE: BLISSGVS ISIN Code: INE416D01022
BSE LIVE 10:25 | 05 Dec 167.55 0.05
(0.03%)
OPEN

166.15

HIGH

169.00

LOW

165.30

NSE LIVE 10:26 | 05 Dec 167.60 -0.70
(-0.42%)
OPEN

167.00

HIGH

169.25

LOW

165.00

OPEN 166.15
PREVIOUS CLOSE 167.50
VOLUME 34488
52-Week high 190.70
52-Week low 79.00
P/E 23.27
Mkt Cap.(Rs cr) 1727.44
Buy Price 167.55
Buy Qty 50.00
Sell Price 167.90
Sell Qty 50.00
OPEN 166.15
CLOSE 167.50
VOLUME 34488
52-Week high 190.70
52-Week low 79.00
P/E 23.27
Mkt Cap.(Rs cr) 1727.44
Buy Price 167.55
Buy Qty 50.00
Sell Price 167.90
Sell Qty 50.00

Bliss GVS Pharma Ltd. (BLISSGVS) - Chairman Speech

Company chairman speech

Dear Shareholders

It gives me great pleasure to present our Company’s 31st Annual Report. In anutshell:

• On a consolidated basis revenue increased 34% to Rs. 54689 lacs and PBT was upby 54% to Rs. 14819 lacs. EPS rose to 8.0 vs 5.8 last year on a consolidated basis

• On a standalone basis revenue was steady at Rs. 32638 lacs PBT up 9% to Rs.10021 lacs. EPS rose to 6.3 vs 5.8

As a group the most exciting development last year was the sensational turnaround ofour managed healthcare operations in Kenya which swung the unit into profitability andalso made a telling contribution to our consolidated numbers. Bliss GVS Healthcare Limited(BGHL) operates an innovative Public-Private engagement model to address unmet healthcarerequirements in Kenya through its chain of clinics and partner service providers. Over thecourse of last year BGHL won a USD 35 million contract to manage outpatient healthcareservices of more than 1.5 million members. The successful roll-out of this contract hascreated a solid foundation for BGHL to increase its reach and capture a substantialproportion of this managed healthcare market. On a group level we see significantsynergies in our pharmaceutical operations working in conjunction with our healthcareoperations to consolidate the position of the Bliss GVS brand as a provider of accessibleaffordable and high quality pharmaceutical products and patient care. We have alsoreceived interest in the managed healthcare model from other Sub-Saharan African (SSA)markets where our pharmaceutical operations are very well established. This represents anexciting opportunity that will provide sustainable growth potential for our group.

Our pharmaceuticals business posted stable numbers despite the macroeconomic challengesfaced in most SSA markets. Across the SSA region we remain focused to leverage our marketleading position in anti-malarials to build brands in other segments. We continue toincrease local presence in chosen markets in SSA order to enhance brand penetration andhave better control over the supply-chain. Our persistent investment in R&D hasstarted to yield fruitful results. Last year we added new products in tablets dry powdersachets suppositories and pessaries dosage forms across anti-malarial anti-inflammatoryanti-fungal and laxative therapeutic categories. Looking forward we have a robustpipeline of products in development that we will file for registration over the comingyear across African Russian & CIS South-East Asian and European markets.

It is important to acknowledge the currency devaluations experienced by many commodityproducing nations over the course of last year which have posed additional challenges toexporting products to these countries. This remains a critical risk factor to monitor forall export-focused pharmaceutical companies. It also provides added reason to increase theglobal reach of our products in order to geographically diversify our business.

To conclude I am confident we are in a good position to capitalize on growthopportunities in pharmaceuticals and healthcare across our markets. I would like tosincerely thank all shareholders partners and employees for their support over the lastyear and look forward to this support in taking the Bliss GVS group to new heights in theyears to come.

Yours sincerely

S. N. Kamath

Managing Director

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard